Jacqueline E. Shea, PhD, Chief Executive Officer
Ann M. Ginsberg, MD, PhD, Chief Medical Officer
Daniel Reznikov, Chief Financial Officer
Dereck Tait, MB, ChB, Senior Director, Clinical Development, Aeras Africa
Executive Office Team
Jacqueline E. Shea, PhD
Chief Executive Officer
Dr. Shea is the CEO at Aeras. With more than 20 years in the life sciences, she spent eight years in a variety of senior management roles with Emergent BioSolutions at their UK office, where from 2008 to 2013 she was general manager and vice president of The Oxford-Emergent Tuberculosis Consortium (OETC), an Aeras product development partner on the clinical development of the candidate vaccine, MVA85A. Dr. Shea is well known and widely respected in the TB vaccine development community, where she plays a leading role for Aeras in advancing new TB vaccines for the world.
Prior to Emergent, Dr. Shea served in increasingly responsible roles in vaccine discovery, business development, and external collaborations at Microscience Ltd, from 1998 to 2005, when the company was acquired by Emergent. Whilst at Microscience and Emergent, Dr. Shea led and contributed to several vaccine discovery and development projects against key bacterial pathogens. She started her career as a senior researcher at Imperial College, London, where she contributed to the development of signature-tagged mutagenesis which received a Prix Galien special commendation for excellence in innovative research. Dr. Shea holds five patents, including those for gene identification technology and Salmonella virulence genes. She received a BSc in Applied Biology with First Class Honors from University of Bath and a PhD, from the National Institute for Medical Research.
Ann M. Ginsberg, MD, PhD
Chief Medical Officer
Ann Ginsberg is the Chief Medical Officer. In this role, Dr. Ginsberg oversees all of Aeras’ clinical programs and projects. In addition, Dr. Ginsberg is a member of Aeras’ Portfolio Review Committee and manages its external Vaccine Advisory Committee.
Dr. Ginsberg served as Head of Clinical Development and then Chief Medical Officer at the Global Alliance for TB Drug Development from 2004 to 2011. Prior to her work at the Global Alliance for TB Drug Development, Dr. Ginsberg was Director of Project Management at Merck & Co. and served for 15 years at the U.S. National Institutes of Health in a variety of roles, including Chief of the Respiratory Diseases Branch of the National Institute of Allergy and Infectious Diseases. Trained as a molecular biologist and Board Certified Anatomic Pathologist, Dr. Ginsberg holds a B.A. from Harvard University, an M.D. from Columbia University and a Ph.D. from Washington University. She is the author of numerous scientific publications and recipient of several prominent awards, including the Department of Health and Human Services Secretary’s Award for Distinguished Service in 2000. She has served on multiple global health committees, Advisory Panels, and Boards, and was a former member of Aeras’ Board of Directors.
Senior Leadership Team
Chief Financial Officer
Daniel Reznikov, Chief Financial Officer, is responsible for all financial and fiscal management aspects of Aeras’s operations. In this senior leadership role, he provides leadership and direction for all administrative, business planning, accounting and budgeting efforts of the organization.
Mr. Reznikov has 30 years of financial and administrative management experience. He was previously employed as CFO at The ALS Association, and prior to ALS he worked for 10 years as Vice President of Operations and Finance at The University of Maryland Biotechnology Institute.
Mr. Reznikov has an M.B.A. in Finance and Investments from George Washington University and a Bachelor’s degree from the University of Maryland. He is a certified public accountant.
Dereck Tait, MB ChB
Senior Clinical Director & Office Lead
Dereck Tait is Senior Clinical Director & Office Lead in Aeras Africa in Cape Town. As a key member of the clinical development department, Dr. Tait provides product specific clinical development leadership. Prior to joining Aeras in 2012, Dr. Tait was Director of an independent clinical research consultancy providing expert advice to a number of companies on various aspects of antiviral drug development. Prior to this he served as Chief Medical Officer for Arrow Therapeutics in London for four years, Vice President of Clinical Research at Idenix Pharmaceuticals in Boston for two years, and spent 10 years in clinical research with a focus on anti-infective drug development at the Wellcome Foundation/GlaxoWellcome/GlaxoSmithKline.
Dr. Tait completed his undergraduate medical training at the University of Pretoria in South Africa, and postgraduate training in Microbiology and Virology at the University of KwaZulu-Natal, South Africa and at the Royal Postgraduate Medical School in London.